Chemotherapy-Induced Peripheral Neuropathy

References

• Irwin M. Patients receiving biologic response modifiers: overview of nursing care. Oncol. Nurs. Forum 1987; 14(6)32–37
   PubMedGoogle Scholar
• Ratain M., Golomb H., Bardawil R., Varidman J., Westbrook C., Kaminer L., et al. Durability of responses to interferon-alpha 2B in advanced hairy cell leukemia. Blood 1987; 69(3)872–877
   PubMed Web of Science ®Google Scholar
• Smith J. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interfuron-alpha 2A. Blood 1991; 78(7)1664–1671
   PubMed Web of Science ®Google Scholar
• Vial T., Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994; 10(2)115–150
   PubMed Web of Science ®Google Scholar
• Vaishampayan U. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999; 54: 22–29
   PubMed Web of Science ®Google Scholar
• Merriggioli M., Brown J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000; 23: 433–435
   PubMed Web of Science ®Google Scholar
• Kaplan R., Wiernik P. Neurotoxicity of antineoplastic drugs. Semin. Oncol. 1982; 9(1)103–129
   PubMed Web of Science ®Google Scholar
• Berger T., Malayeri R., Doippelbauer A., Krajnik G., Huber H., Auff E., et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur. J. Cancer 1997; 39(9)1393–1399
   Google Scholar
• Nagy J.L., Adelstein D.J., Newman C.W., Rybicki L.A., Rice T.W., Lavertu P. Cisplatin ototoxicity: the importance of baseline audiometry. Am. J. Clin. Oncol. 1999; 22(3)305–308
   PubMed Web of Science ®Google Scholar
• Petrini M., Vaglini F., Cervetti G., Cavalletti M., Sartucci F., Murri L., Corsini G.U. Is lithium able to reverse neurological damage induced by vinca alkaloids?. J. Neurol. Transm. 1999; 106(5–6)569–575
   PubMed Web of Science ®Google Scholar
• Armstrong T., Rust D., Kohtz J. Neurologic, pulmonary and cutaneous toxicities of hgh-dose chemotherapy. Oncol. Nurs. Forum Suppl. 1997; 24(1)23–33
   PubMedGoogle Scholar
• Gastineau D., Habermann T., Hermann R. Severe neuropathy associated with low-dose recombinant interferon-alpha. Am. J. Med. 1989; 87: 116
   PubMed Web of Science ®Google Scholar
• Gotaskie G., Andreassi B. Paclitaxel: a new antitotic chemotherapeutic agent. Cancer Practice 1994; 2(4)27–33
   PubMedGoogle Scholar
• Bromberg M. Peripheral neurotoxic disorders. Neurol. Clin. 2000; 18(3)681–694
   PubMed Web of Science ®Google Scholar
• Postma T., Heimans J. Grading chemotherapy-induced peripheral neuropathy. Ann. Oncol. 2000; 11: 509–513
   PubMed Web of Science ®Google Scholar
• Spencer P.S., Schaumburg H.H. An expanded classification of neurotoxic responses based on cellular targets of chemical agents. Acta Neurol. Scand. 1984; 100: 9–19
   Google Scholar
• Cavanaugh J.B. The significance of the “dying back” process in experimental and human neurological disease. Int. Rev. Exp. Pathol. 1964; 3: 219
   PubMedGoogle Scholar
• Schroenal R., Cavanaugh J.B. Mechanisms involved in the “dying back” process—a hypothesis implicating coenzymes. Neuropathol. Appl. Neurobiol. 1977; 3: 145–145
   Web of Science ®Google Scholar
• Meijeer C., de Vries E.G., Marmiroli P., Tredici G., Frattola L., Cavaletti G. Cisplatin-indiced DNA-platination in experimental dosal root ganglia neuronopathy. Neurotoxicology 1999; 20(6)883–887
   PubMed Web of Science ®Google Scholar
• Chaudhuri K.R., Thomaides T., Mathias C.J. Inability to constrict actively the superior mesenteric artery in human autonomic failure. J. Physiol. 1991; 438: 1–95
   Google Scholar
• Hartmann J., Kollmannsberger C., Lanz L., Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer 1999; 83: 866–869
   PubMed Web of Science ®Google Scholar
• Helson L., Okonkkwo E., Anton L., Cvitkovic E. Cis-platinum ototoxicity. Clin. Toxicol. 1978; 13: 469–478
   PubMed Web of Science ®Google Scholar
• Schaefer S.D., Post J., Close L.G., Wright C.G. Ototoxicity of low and moderate dose cisplatin. Cancer 1985; 58(8)1934–1939
   Google Scholar
• Waters G., Ahmad M., Katsarkas A., Stanimir G., McKay J. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hearing 1991; 12(2)91–102
   PubMed Web of Science ®Google Scholar
• Bokemeyer C., Berger C., Hartman J., Kollmansberger C., Schmoll H., Kuczyk M., et al. Analysis of risk factors of cisplatin-indiced ototoxicity in patients with testicular cancer. Br. J. Cancer 1998; 77(1355)1362
   Google Scholar
• Stadnicki S., Fleischman R, Schaeppi U. Cisdiamminedichloroplatinum (II) induced ototoxicity in guinea pigs. 16–18
   Google Scholar
• Hulst R.J., Dreschler W.U.N. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann. Otol. Rhinol. Laryngol. 1988; 97(2)133–137
   PubMed Web of Science ®Google Scholar
• Redell R., Kefford R.G.J.C.A.F.R.T.M. Ototoxicity in patients receiving cisplatin. Importance of dose and method of drug administration. Cancer Treat. Rep. 1982; 66: 19–23
   PubMedGoogle Scholar
• Ettinger L.J., Douglas H.O.H.D.M.E.R.N.F.G.J.F.A.I. Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteoscarcoma. Cancer 1981; 47(2)248–254
   PubMed Web of Science ®Google Scholar
• Pedersen K.E., Rosenhall U. Moller, M.B. Longitudinal study of changes in speech perception between 70 and 81 years of age. Audiology 1989; 30(4)201–211
   Google Scholar
• Ostrow S., Hahn D., Wiernik P., Richards R.D., Moller M.B. Opthalmic toxicity after cis-dichlorodiammineplatinum (II) therapy. Cancer Treat. Rep. 1978; 62(10)1591–1594
   PubMedGoogle Scholar
• Becher R., Schutt P., Osieka R., Schmidt C.G. Peripheral neuropathy and ophthalmic toxicity after treatment with cis-dichlorodiaminoplatinum II. J. Cancer Res. Clin. Oncol. 1980; 96(2)219–222
   PubMed Web of Science ®Google Scholar
• Berman I.J., Mann M.P. Seizures and transient cortical blindness associated with cis-platinum (II) (PPD) therapy in thirty-year old man. Cancer 1980; 45(4)764–766
   PubMed Web of Science ®Google Scholar
• Wilding G., Caruso R., Lawernce T., Ostchega Y., Ballintine E., Young R., Ozols R. Retinal toxicity after high dose cisplatin therapy. J. Clin. Oncol. 1985; 3(12)1683–1689
   PubMed Web of Science ®Google Scholar
• Roelofs R., Hrushesky W., Rogin J., Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984; 34(7)934–938
   PubMed Web of Science ®Google Scholar
• Missit J. Oxaliplatin in practice. Br. J. Cancer 1998; 77(4)4–7
   PubMedGoogle Scholar
• Manesis E., Petrou C., Brouzas D., Hadziyannis S. Optic tract neuropathy complicating low-dose inteferon treatment. J. Hepatol. 1994; 21: 474–477
   PubMed Web of Science ®Google Scholar
• Quattrinin A., Comi G., Nemni R., Martinelli V., Villa A., Cami M., et al. Axonal neuropathy associated with interferon-alpha treatment for hepatitis C: HLA-DR immunoreactivity in Schwann cells. Acta Neuropathol. 1997; 94: 504–508
   PubMed Web of Science ®Google Scholar
• Rutkove S. An unusual anxonal polyneuropathy indiced by low dose interfuron alpha 2a. Arch. Neurol. 1997; 54(7)907–908
   PubMedGoogle Scholar
• Marzo M.E., Tintore M., Fabregues O., Montalban X., Codina A. Chronic inflammatory demylinating polyneuropathy during treatment with interfuron-alpha. J. Neurol. Neurosurg. Psychiatry 1998; 65(4)604
   PubMed Web of Science ®Google Scholar
• Anthoney D.A., Bone I.E.T.R. Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma. Ann. Oncol. 2000; 11(9)1197–1200
   PubMed Web of Science ®Google Scholar
• Sandler S.G., Tobin W.H.E.S. Vincristine induced neuropathy: a clinical study of fifty leukemic patients. Neurology 1969; 19(4)367–374
   PubMed Web of Science ®Google Scholar
• Hollans J.F., Scharlau C., Gailani S., Krant M.J., Olson K.B., Horton J., Shnider B.I., Lynch J.J., Owens A., Carbone P.P., Colsky J., Grob D., Miller S.P., Hall T.C. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 1973; 33(6)1258–1264
   PubMed Web of Science ®Google Scholar
• Pal P. Peripheral and electrophysiological studies in vincristine induced neuropathy. Electromyogr. Clin. Neurophysiol. 1999; 39(6)323–330
   PubMedGoogle Scholar
• Postma T.J., Benard B.A., Huijgens P., Ossenkoppele G.J., Heimans J.J. Long-term effects of vincristine on the peripheral nervous system. J. Neuro-Oncol. 1993; 15(1)23–27
   PubMed Web of Science ®Google Scholar
• Weiss H.D., Walker M., Wiernik P.H. Neurotoxicity of commonly used antineoplastic agents. N. Engl. J. Med. 1974; 291(3)127–133
   PubMed Web of Science ®Google Scholar
• Hilkens P.H., Verweij J.S. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46(1)104–108
   PubMed Web of Science ®Google Scholar
• Lipton R.B., Apfel S., Dutcher R.K., Rosenberg R., Kaplan J., Berger A., et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39(3)368–373
   PubMed Web of Science ®Google Scholar
• Forsyth P.A., Balmaceda C., Peterson K., Seidman A.D., Brasher P., DeAngelis L.M. Prospective study of paclitaxel-induced neuropathy with quantitative sensory testing. J. Neuro-Oncol. 1997; 51(2)47–53
   Google Scholar
• Postma T., Vermorken J.B., Liefting A.J., Pinedo H.M., Heimans J.J. Paclitaxel-induced neuropathy. Ann. Oncol. 1995; 6(5)489–494
   PubMed Web of Science ®Google Scholar
• McDougall A., McLeod J. Autonomic neuropathy I. J. Neurol. Sci. 1996; 137(2)79–88
   PubMed Web of Science ®Google Scholar
• Elkholm E., Rantenen V., Antila K., Salminen E. Paclitaxel changes sympathetic control of blood pressure. Eur. J. Cancer 1997; 33(9)1419–1424
   PubMed Web of Science ®Google Scholar
• Jerian S.M., Sarosy G., Link C.J., Fingert H.J., Reed E., Kohn E.C. Incapacitating autonomic neuropathy precipitated by taxol. Gynecol. Oncol. 1993; 51(2)277–280
   PubMed Web of Science ®Google Scholar
• Zhang P., Wang S.Y., Hu X.H. Arsenic treated 72 cases of acute promyelocytic leukemia. Chin. J. Hematol. 1996; 17: 58–62
   Google Scholar
• Novick S.C., Warrell R.P. Arsenicals in Hematologic. Semin. Oncol. 2000; 27(5)495–501
   PubMed Web of Science ®Google Scholar
• Westervelt P., Pollock J., Haug J. Response and toxicity associated with dose escalation of arsenic trioxide in treatment of resistant acute promyelocytic leukemia. Blood 1997; 90: 249b
   Google Scholar
• Chaudhry V., Rowinsky E.K., Sartorius S.E., Donehower R.C., Cornblath D.R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann. Neurol. 1994; 35(3)304–311
   PubMed Web of Science ®Google Scholar
• Cavaletti G., Boglium G., Zincone A., Mazorati L., Melzi P., Frattola L., Marzola M., Bonazzi C., Cantu M.G., Chiari S., Galli A., Bregni M., Gianni M.A. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. Br. J. Cancer 1997; 15(1)199–206
   Google Scholar
• Hilkens P., Verweij J., Vecht C.J., Stoter G., ven den Bent M.J. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br. J. Cancer 1997; 75(3)417–422
   PubMed Web of Science ®Google Scholar
• Postma T., Hoekman K., van Riel J.M., Heimans J.J., Vermorken J.B. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J. Neuro-Oncol. 1999; 45(3)241–246
   PubMed Web of Science ®Google Scholar
• Hildebrandt G., Holler E., Woenkhaus M., Quarch G., Reichle A., Schslke B., et al. Acute deterioration of Charcot-Marie-Tooth disease 1A (CMT 1A) following 2 mg. of vincristine chemotherapy. Ann. Oncol. 2000; 11: 743–747
   PubMed Web of Science ®Google Scholar
• Graf W.D., Chance P., Lensch M.W., Eng L.J., Lipe H.P., Bird T.D. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996; 77(7)1356–1362
   PubMed Web of Science ®Google Scholar
• Uno S., Katayama K., Dobashi N., Hirano A., Ogihara A., Yamazaki H., Usui N., Kobayashi T., Inoune, Kuraishi Y. Acute vincristine neurotoxicity in non-Hodgekin's lymphoma patient with Charcot-Marie-Tooth disease. Jpn. J. Clin. Hematol. 1999; 40(5)414–419
   PubMedGoogle Scholar
• Wokke J., van Dijk G. Sensory neuropathies including painful and toxic neuropathies. J. Neurol. 1997; 244: 209–221
   PubMed Web of Science ®Google Scholar
• McDougall A., McLeod J. Autonomic neuropathy II: specific peripheral neuropathies. J. Neurol. Sci. 1996; 138: 1–13
   PubMed Web of Science ®Google Scholar
• Postma T., Heimans J., Muller M., Ossenkopple G., Vermoken J., Aaronson N. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann. Oncol. 1998; 9(7)739–744
   PubMed Web of Science ®Google Scholar
• Postma T., Heimans J., Muller M., Ossenkopple G., Vermorken J., Aronson N. Pitfalls in grading severity of chemotherapy induced peripheral neuropathy. Ann. Oncol. 1998; 9: 739–744
   PubMed Web of Science ®Google Scholar
• Lipton R.B., Bradley S., Galer B.S., Dutcher R.K., Portenoy R.K., Berger A., et al. Quantitative sensory testing demonstrates that subclinical sensory neuropathy is prevalent in patients with cancer. Arch. Neurol. 1987; 44: 944–946
   PubMed Web of Science ®Google Scholar
• Lipton R.B., Galer B.S., Dutcher R.K., Portenoy R.K., Meller F., Arezzo J.C., et al. Large and small fibre type sensory dysfunction in patients with cancer. J. Neurol. Neurosurg. Psychiatry 1991; 54(8)706–709
   PubMed Web of Science ®Google Scholar
• Ostchega Y., et al. High dose cisplatin related peripheral neuropathy. Cancer Nurs. 1988; 11(1)23–32
   PubMed Web of Science ®Google Scholar
• Viele C., Holmes B. Amifostine: drug profile and nursing implications of the first pancytoprotectant. Oncol. Nurs. Forum 1998; 25(3)515–523
   PubMedGoogle Scholar
• Penz M., Kornek G., Raderer M., Ulrichpur H., Fiebigier W., Schiethauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensistive neuropathy. Ann. Oncol. 2001; 12(3)421–422
   PubMed Web of Science ®Google Scholar
• Boyle F.M., Wheeler H., Shenfield G.M. Glutamate ameliorates experimental vincristine neuropathy. J. Pharmacol. Exp. Ther. 1996; 279(1)410–415
   PubMed Web of Science ®Google Scholar
• Boyle F.M., Wheeler H., Shenfield G.M. Amerlioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J. Neuro-Oncol. 1999; 41(2)107–116
   PubMed Web of Science ®Google Scholar
• Apfel S. Neurotrophic factors in peripheral neuropathies: therapeutic implications. Brain Pathol. 1999; 9(2)393–413
   PubMed Web of Science ®Google Scholar
• De Santis S., et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin. Cancer Res. 2000; 6(1)90–95
   PubMed Web of Science ®Google Scholar
• Mc Arthur J., et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS clinical trials group team 291. Neurology 2000; 54(5)1080–1088
   PubMed Web of Science ®Google Scholar
• Pachter B.R., Eberstein A. Passive exercise and reinnervation of the rat derived extensor digitorum longus muscle after nerve crush. Am. J. Phys. Med. Rehabil. 2000; 68(4)179–182
   Google Scholar
• Herbison G.J., Jaweed M.N.D.J. Acetylcholine sensitivity and fibrillation potentials in electrically stimulated crush-denervated rat skeletal muscle. Arch. Phys. Med. Rehabil. 1983; 64(5)217–220
   PubMed Web of Science ®Google Scholar
• Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3h) employed in the treatment of gynecologic malignancies. J. Cancer Res. Clin. Oncology 2001; 127(1)55–58
   PubMed Web of Science ®Google Scholar